Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.

Humans Female Virulence BRCA1 Protein / genetics BRCA2 Protein / genetics Ovarian Neoplasms / genetics Genetic Predisposition to Disease Breast Neoplasms

Journal

British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635

Informations de publication

Date de publication:
06 2023
Historique:
received: 07 11 2022
accepted: 24 03 2023
revised: 22 02 2023
medline: 7 6 2023
pubmed: 20 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

The distribution of ovarian tumour characteristics differs between germline BRCA1 and BRCA2 pathogenic variant carriers and non-carriers. In this study, we assessed the utility of ovarian tumour characteristics as predictors of BRCA1 and BRCA2 variant pathogenicity, for application using the American College of Medical Genetics and the Association for Molecular Pathology (ACMG/AMP) variant classification system. Data for 10,373 ovarian cancer cases, including carriers and non-carriers of BRCA1 or BRCA2 pathogenic variants, were collected from unpublished international cohorts and consortia and published studies. Likelihood ratios (LR) were calculated for the association of ovarian cancer histology and other characteristics, with BRCA1 and BRCA2 variant pathogenicity. Estimates were aligned to ACMG/AMP code strengths (supporting, moderate, strong). No histological subtype provided informative ACMG/AMP evidence in favour of BRCA1 and BRCA2 variant pathogenicity. Evidence against variant pathogenicity was estimated for the mucinous and clear cell histologies (supporting) and borderline cases (moderate). Refined associations are provided according to tumour grade, invasion and age at diagnosis. We provide detailed estimates for predicting BRCA1 and BRCA2 variant pathogenicity based on ovarian tumour characteristics. This evidence can be combined with other variant information under the ACMG/AMP classification system, to improve classification and carrier clinical management.

Sections du résumé

BACKGROUND
The distribution of ovarian tumour characteristics differs between germline BRCA1 and BRCA2 pathogenic variant carriers and non-carriers. In this study, we assessed the utility of ovarian tumour characteristics as predictors of BRCA1 and BRCA2 variant pathogenicity, for application using the American College of Medical Genetics and the Association for Molecular Pathology (ACMG/AMP) variant classification system.
METHODS
Data for 10,373 ovarian cancer cases, including carriers and non-carriers of BRCA1 or BRCA2 pathogenic variants, were collected from unpublished international cohorts and consortia and published studies. Likelihood ratios (LR) were calculated for the association of ovarian cancer histology and other characteristics, with BRCA1 and BRCA2 variant pathogenicity. Estimates were aligned to ACMG/AMP code strengths (supporting, moderate, strong).
RESULTS
No histological subtype provided informative ACMG/AMP evidence in favour of BRCA1 and BRCA2 variant pathogenicity. Evidence against variant pathogenicity was estimated for the mucinous and clear cell histologies (supporting) and borderline cases (moderate). Refined associations are provided according to tumour grade, invasion and age at diagnosis.
CONCLUSIONS
We provide detailed estimates for predicting BRCA1 and BRCA2 variant pathogenicity based on ovarian tumour characteristics. This evidence can be combined with other variant information under the ACMG/AMP classification system, to improve classification and carrier clinical management.

Identifiants

DOI: 10.1038/s41416-023-02263-5 PMID: 37076566 PMC: PMC10241792
pubmed: 37076566
doi: 10.1038/s41416-023-02263-5
pii: 10.1038/s41416-023-02263-5
pmc: PMC10241792
doi:

Substances chimiques

BRCA1 Protein 0
BRCA2 Protein 0
BRCA1 protein, human 0
BRCA2 protein, human 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2283-2294

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR000124
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA128978
Pays : United States
Organisme : Cancer Research UK
ID : 20861
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U19 CA148065
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180822
Pays : United States
Organisme : NCI NIH HHS
ID : RC4 CA153828
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180888
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA112486
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA260132
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148112
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA140323
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214545
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Cancer Research UK
ID : 23382
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 15601
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : P20 GM130423
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA164920
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180868
Pays : United States
Organisme : Cancer Research UK
ID : 22905
Pays : United Kingdom
Organisme : NCATS NIH HHS
ID : UL1 TR001881
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148537
Pays : United States

Investigateurs

Marian J E Mourits (MJE)
Fabienne Lesueur (F)
Anna De Fazio (A)
Miguel de la Hoya (M)
Thomas van Overeem Hansen (T)
Elizabeth Santana Dos Santos (ES)

Informations de copyright

© 2023. The Author(s).

Références

Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20:207–25.
pubmed: 16359925 doi: 10.1016/j.bpobgyn.2005.10.007
Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41–4.
pubmed: 14668549 doi: 10.1097/01.pgp.0000101080.35393.16
Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds). WHO classification of tumours of female reproductive organs, 4th edn. Lyon, France: International Agency for Research on Cancer; 2014.
Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–8.
pubmed: 15111296 pmcid: 1615664 doi: 10.1016/S0002-9440(10)63708-X
Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.
pubmed: 19053170 pmcid: 2592352 doi: 10.1371/journal.pmed.0050232
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.
pubmed: 12677558 pmcid: 1180265 doi: 10.1086/375033
Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst. 2015;107:djv214.
pubmed: 26315354 pmcid: 4643629 doi: 10.1093/jnci/djv214
Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol. 2015;33:2901–7.
pubmed: 26261251 pmcid: 4554751 doi: 10.1200/JCO.2015.61.2408
Lilyquist J, LaDuca H, Polley E, Davis BT, Shimelis H, Hu C, et al. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol Oncol. 2017;147:375–80.
pubmed: 28888541 pmcid: 5801741 doi: 10.1016/j.ygyno.2017.08.030
Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004;10:2473–81.
pubmed: 15073127 doi: 10.1158/1078-0432.CCR-1029-3
Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol. 2012;120:235–40.
pubmed: 22776961 doi: 10.1097/AOG.0b013e31825f3576
Malander S, Ridderheim M, Måsbäck A, Loman N, Kristoffersson U, Olsson H, et al. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer. 2004;40:422–8.
pubmed: 14746861 doi: 10.1016/j.ejca.2003.09.016
Biglia N, Sgandurra P, Bounous VE, Maggiorotto F, Piva E, Pivetta E, et al. Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival. Ecancermedicalscience. 2016;10:639.
pubmed: 27350785 pmcid: 4898941 doi: 10.3332/ecancer.2016.639
Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014;23:4703–9.
pubmed: 24728189 pmcid: 4119409 doi: 10.1093/hmg/ddu172
Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, et al. Germline and somatic BRCA1/2 gene mutational status and clinical outcomes in epithelial peritoneal, ovarian, and fallopian tube cancer: over a decade of experience in a single institution in Korea. Cancer Res Treat. 2020;52:1229–41.
pubmed: 32718143 pmcid: 7577800
Soegaard M, Kjaer SK, Cox M, Wozniak E, Høgdall E, Høgdall C, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res. 2008;14:3761–7.
pubmed: 18559594 doi: 10.1158/1078-0432.CCR-07-4806
Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, et al. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). J Med Genet. 2019;56:574–80.
pubmed: 30979843 doi: 10.1136/jmedgenet-2018-105930
Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482–90.
pubmed: 26720728 pmcid: 4845939 doi: 10.1001/jamaoncol.2015.5495
Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807–16.
pubmed: 16284991 doi: 10.1002/cncr.21536
Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:77–102.
pubmed: 33406487 doi: 10.6004/jnccn.2021.0001
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38:1222–45.
pubmed: 31986064 doi: 10.1200/JCO.19.02960
Arts-de Jong M, de Bock GH, van Asperen CJ, Mourits MJ, de Hullu JA, Kets CM. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. Eur J Cancer. 2016;61:137–45.
pubmed: 27209246 doi: 10.1016/j.ejca.2016.03.009
Marth C, Hubalek M, Petru E, Polterauer S, Reinthaller A, Schauer C, et al. AGO Austria recommendations for genetic testing of patients with ovarian cancer. Wien Klin Wochenschr. 2015;127:652–4.
pubmed: 26109557 pmcid: 4536270 doi: 10.1007/s00508-015-0814-7
Panchal SM, Ennis M, Canon S, Bordeleau LJ. Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Med Genet. 2008;9:116.
pubmed: 19102775 pmcid: 2630980 doi: 10.1186/1471-2350-9-116
Murray ML, Cerrato F, Bennett RL, Jarvik GP. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med. 2011;13:998–1005.
pubmed: 21811163 doi: 10.1097/GIM.0b013e318226fc15
Vos J, Otten W, van Asperen C, Jansen A, Menko F, Tibben A. The counsellees’ view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psychooncology. 2008;17:822–30.
pubmed: 18157792 doi: 10.1002/pon.1311
Richter S, Haroun I, Graham TC, Eisen A, Kiss A, Warner E. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. Ann Oncol. 2013;24:viii69–viii74.
pubmed: 24131974 doi: 10.1093/annonc/mdt312
Moghadasi S, Eccles DM, Devilee P, Vreeswijk MP, van Asperen CJ. Classification and clinical management of variants of uncertain significance in high penetrance cancer predisposition genes. Hum Mutat. 2016;37:331–6.
pubmed: 26777316 doi: 10.1002/humu.22956
Eccles DM, Mitchell G, Monteiro AN, Schmutzler R, Couch FJ, Spurdle AB, et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol. 2015;26:2057–65.
pubmed: 26153499 pmcid: 5006185 doi: 10.1093/annonc/mdv278
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.
pubmed: 25741868 pmcid: 4544753 doi: 10.1038/gim.2015.30
Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med. 2008;10:294–300.
pubmed: 18414213 doi: 10.1097/GIM.0b013e31816b5cae
Tavtigian SV, Greenblatt MS, Harrison SM, Nussbaum RL, Prabhu SA, Boucher KM, et al. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med. 2018;20:1054–60.
pubmed: 29300386 pmcid: 6336098 doi: 10.1038/gim.2017.210
Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet. 2004;75:535–44.
pubmed: 15290653 pmcid: 1182042 doi: 10.1086/424388
Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, et al. ENIGMA–evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 2012;33:2–7.
pubmed: 21990146 doi: 10.1002/humu.21628
Lindor NM, Guidugli L, Wang X, Vallée MP, Monteiro AN, Tavtigian S, et al. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat. 2012;33:8–21.
pubmed: 21990134 doi: 10.1002/humu.21627
Lovelock PK, Spurdle AB, Mok MT, Farrugia DJ, Lakhani SR, Healey S, et al. Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res. 2007;9:R82.
pubmed: 18036263 pmcid: 2246181 doi: 10.1186/bcr1826
Köbel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, et al. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev. 2013;22:1677–86.
pubmed: 23880734 pmcid: 3955399 doi: 10.1158/1055-9965.EPI-13-0391
Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654–63.
pubmed: 22711857 pmcid: 3413277 doi: 10.1200/JCO.2011.39.8545
Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res. 1998;4:2433–7.
pubmed: 9796975
Choi MC, Heo JH, Jang JH, Jung SG, Park H, Joo WD, et al. Germline mutations of BRCA1 and BRCA2 in Korean ovarian cancer patients: finding founder mutations. Int J Gynecol Cancer. 2015;25:1386–91.
pubmed: 26402875 doi: 10.1097/IGC.0000000000000529
Rust K, Spiliopoulou P, Tang CY, Bell C, Stirling D, Phang T, et al. Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience. BJOG. 2018;125:1451–8.
pubmed: 29460478 doi: 10.1111/1471-0528.15171
Koopman PAR. Confidence intervals for the ratio of two binomial proportions. Biometrics. 1984;40:513–7.
doi: 10.2307/2531405
Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16:267–82.
pubmed: 19700937 pmcid: 2745605 doi: 10.1097/PAP.0b013e3181b4fffa
Lim D, Murali R, Murray MP, Veras E, Park KJ, Soslow RA. Morphological and immunohistochemical reevaluation of tumors initially diagnosed as ovarian endometrioid carcinoma with emphasis on high-grade tumors. Am J Surg Pathol. 2016;40:302–12.
pubmed: 26551621 pmcid: 4994535 doi: 10.1097/PAS.0000000000000550

Auteurs

Denise G O'Mahony (DG)

Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, Nicosia, 2371, Cyprus.
Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, 2371, Cyprus.
ORCID: 0000-0002-7212-0920

Susan J Ramus (SJ)

School of Clinical Medicine, University of New South Wales Medicine and Health, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.
Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.
ORCID: 0000-0003-0005-7798

Melissa C Southey (MC)

Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, 3168, Australia.
Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, 3010, Australia.
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, 3004, Australia.

Nicola S Meagher (NS)

School of Clinical Medicine, University of New South Wales Medicine and Health, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.
Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia.
ORCID: 0000-0001-9134-2118

Andreas Hadjisavvas (A)

Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, 2371, Cyprus.

Esther M John (EM)

Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94304, USA.

Ute Hamann (U)

Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.

Evgeny N Imyanitov (EN)

N.N. Petrov Institute of Oncology, St. Petersburg, 197758, Russia.

Irene L Andrulis (IL)

Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, M5G 1×5, Canada.
Department of Molecular Genetics, University of Toronto, Toronto, ON, M5S 1A8, Canada.
ORCID: 0000-0002-4226-6435

Priyanka Sharma (P)

Department of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS, 66205, USA.

Mary B Daly (MB)

Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.

Christopher R Hake (CR)

Waukesha Memorial Hospital-Pro Health Care, Waukesha, WI, 53188, USA.

Jeffrey N Weitzel (JN)

The University of Kansas Cancer Center, Kansas City, MO, 66160, USA.
ORCID: 0000-0001-6714-092X

Anna Jakubowska (A)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, 171-252, Poland.
Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, 171-252, Poland.
ORCID: 0000-0002-5650-0501

Andrew K Godwin (AK)

Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS, 66160, USA.
ORCID: 0000-0002-3987-9580

Adalgeir Arason (A)

Department of Pathology, Landspitali University Hospital, Reykjavik, 101, Iceland.
BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik, 101, Iceland.
ORCID: 0000-0003-0480-886X

Anita Bane (A)

Department of Pathology & Molecular Medicine, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, L8V 1C3, Canada.

Jacques Simard (J)

Genomics Center, Centre Hospitalier Universitaire de Québec - Université Laval Research Center, Québec City, QC, G1V 4G2, Canada.
ORCID: 0000-0001-6906-3390

Penny Soucy (P)

Genomics Center, Centre Hospitalier Universitaire de Québec - Université Laval Research Center, Québec City, QC, G1V 4G2, Canada.

Maria A Caligo (MA)

SOD Genetica Molecolare, University Hospital, Pisa, 56126, Italy.

Phuong L Mai (PL)

Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.

Kathleen B M Claes (KBM)

Centre for Medical Genetics, Ghent University, Gent, 9000, Belgium.

Manuel R Teixeira (MR)

Department of Laboratory Genetics, Portuguese Oncology Institute of Porto (IPO Porto)/Comprehensive Cancer Center, Porto, 4200-072, Portugal.
School of Medicine and Biomedical Sciences Institute (ICBAS), University of Porto, Porto, 4050-013, Portugal.
ORCID: 0000-0002-4896-5982

Wendy K Chung (WK)

Departments of Pediatrics and Medicine, Columbia University, New York, NY, 10032, USA.
ORCID: 0000-0003-3438-5685

Conxi Lazaro (C)

Hereditary Cancer Program, ONCOBELL-IDIBELL-IGTP, Catalan Institute of Oncology, CIBERONC, Barcelona, 08908, Spain.

Peter J Hulick (PJ)

Center for Medical Genetics, NorthShore University HealthSystem, Evanston, IL, 60201, USA.
The University of Chicago Pritzker School of Medicine, Chicago, IL, 60637, USA.
ORCID: 0000-0001-8397-4078

Amanda E Toland (AE)

Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, 43210, USA.
ORCID: 0000-0002-0271-1792

Inge Sokilde Pedersen (IS)

Molecular Diagnostics, Aalborg University Hospital, Aalborg, 9000, Denmark.
Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, 9000, Denmark.
Department of Clinical Medicine, Aalborg University, Aalborg, 9000, Denmark.
ORCID: 0000-0002-9902-8040

Susan L Neuhausen (SL)

Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.
ORCID: 0000-0001-5053-0390

Ana Vega (A)

Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, 28029, Spain.
Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, 15706, Spain.
Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, 15706, Spain.
ORCID: 0000-0002-7416-5137

Miguel de la Hoya (M)

Molecular Oncology Laboratory, CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, 28040, Spain.
ORCID: 0000-0002-8113-1410

Heli Nevanlinna (H)

Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, 00290, Finland.
ORCID: 0000-0002-0916-2976

Mallika Dhawan (M)

Cancer Genetics and Prevention Program, University of California San Francisco, San Francisco, CA, 94143-1714, USA.

Valentina Zampiga (V)

Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

Rita Danesi (R)

Romagna Cancer Registry, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, 47014, Italy.

Liliana Varesco (L)

Unit of Hereditary Cancer, IRCCS Ospedale Policlinico San Martino, Genoa, 16132, Italy.

Viviana Gismondi (V)

Unit of Hereditary Cancer, IRCCS Ospedale Policlinico San Martino, Genoa, 16132, Italy.

Valerio Gaetano Vellone (VG)

Unit of Pathology, IRCCS Ospedale Policlinico San Martino, Genoa, 16132, Italy.

Paul A James (PA)

Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14049-900, Brazil.

Ramunas Janavicius (R)

Faculty of Medicine, Institute of Biomedical Sciences, Department of Human and Medical Genetics, Vilnius University, Vilnius, LT-03101, Lithuania.
State Research Institute Centre for Innovative Medicine, Vilnius, 8410, Lithuania.

Liene Nikitina-Zake (L)

Latvian Biomedical Research and Study Centre, Riga, LV-1067, Latvia.

Finn Cilius Nielsen (FC)

Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK-2100, Denmark.

Thomas van Overeem Hansen (T)

Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK-2100, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, , University of Copenhagen, Copenhagen, 2200, Denmark.

Tanja Pejovic (T)

Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, 97239, USA.
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.

Ake Borg (A)

Department of Oncology, Lund University and Skåne University Hospital, Lund, 222 41, Sweden.

Johanna Rantala (J)

Clinical Genetics, Karolinska Institutet, Stockholm, 171 76, Sweden.

Kenneth Offit (K)

Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

Marco Montagna (M)

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, 35128, Italy.

Katherine L Nathanson (KL)

Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19066, USA.
ORCID: 0000-0002-6740-0901

Susan M Domchek (SM)

Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19066, USA.

Ana Osorio (A)

Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, 28029, Spain.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, 28029, Spain.
Genetics Service, Fundación Jiménez Díaz, Madrid, 28040, Spain.
ORCID: 0000-0001-8124-3984

María J García (MJ)

Computational Oncology Group, Structural Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, 28029, Spain.
ORCID: 0000-0002-2236-9912

Beth Y Karlan (BY)

David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, 90095, USA.
ORCID: 0000-0002-9451-2933

Anna De Fazio (A)

The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia.
Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, Australia.
Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, 2145, Australia.
The University of Sydney, Sydney, NSW, 2145, Australia.
ORCID: 0000-0003-0057-4744

David Bowtell (D)

Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, 3000, Australia.

Lesley McGuffog (L)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK.

Goska Leslie (G)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK.
ORCID: 0000-0001-5756-6222

Michael T Parsons (MT)

Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Thilo Dörk (T)

Gynaecology Research Unit, Hannover Medical School, Hannover, 30625, Germany.
ORCID: 0000-0002-9458-0282

Lisa-Marie Speith (LM)

Gynaecology Research Unit, Hannover Medical School, Hannover, 30625, Germany.

Elizabeth Santana Dos Santos (ES)

Service de Génétique, Institut Curie, Paris, 75005, France.
Oncology Center, Hospital Sirio-Libanes, São Paulo, 01308-050, Brazil.
Department of Clinical Oncology, A.C.Camargo Cancer Center, São Paulo, 1509900, Brazil.

Alexandre André B A da Costa (AABA)

Department of Clinical Oncology, A.C.Camargo Cancer Center, São Paulo, 1509900, Brazil.
Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, 2215, USA.

Paolo Radice (P)

Unit of Preventive Medicine: Molecular Bases of Genetic Risk, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, 20133, Italy.

Paolo Peterlongo (P)

Genome Diagnostics Program, IFOM ETS - the AIRC Institute of Molecular Oncology, Milan, 20139, Italy.
ORCID: 0000-0001-6951-6855

Laura Papi (L)

Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', Medical Genetics Unit, University of Florence, Florence, 27571, Italy.

Christoph Engel (C)

Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, 04107, Germany.
LIFE - Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, 04103, Germany.

Eric Hahnen (E)

Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany.
Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany.

Rita K Schmutzler (RK)

Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany.
Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany.
Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany.

Barbara Wappenschmidt (B)

Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany.
Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany.

Douglas F Easton (DF)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK.
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK.
ORCID: 0000-0003-2444-3247

Marc Tischkowitz (M)

Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montréal, QC, H4A 3J1, Canada.
Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, CB2 0QQ, UK.

Christian F Singer (CF)

Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.
ORCID: 0000-0003-1294-0027

Yen Yen Tan (YY)

Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.

Alice S Whittemore (AS)

Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Weiva Sieh (W)

Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
ORCID: 0000-0003-0085-1190

James D Brenton (JD)

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 0RE, UK.
ORCID: 0000-0002-5738-6683

Drakoulis Yannoukakos (D)

Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, 15310, Greece.

Florentia Fostira (F)

Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, 15310, Greece.

Irene Konstantopoulou (I)

Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, 15310, Greece.
ORCID: 0000-0002-0470-0309

Jana Soukupova (J)

Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 12000, Czech Republic.
ORCID: 0000-0003-2413-1542

Michal Vocka (M)

Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 12000, Czech Republic.
ORCID: 0000-0002-9386-657X

Georgia Chenevix-Trench (G)

Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Paul D P Pharoah (PDP)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK.
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK.
ORCID: 0000-0001-8494-732X

Antonis C Antoniou (AC)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK.

David E Goldgar (DE)

Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.

Amanda B Spurdle (AB)

Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
ORCID: 0000-0003-1337-7897

Kyriaki Michailidou (K)

Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, Nicosia, 2371, Cyprus. kyriakimi@cing.ac.cy.
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK. kyriakimi@cing.ac.cy.
ORCID: 0000-0001-7065-1237

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Ovarian cancer pathology characteristics as...
questionsmedicales.fr › Phénomènes microbiologiques › Virulence › Ovarian cancer pathology characteristics as...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéine BRCA1 › Ovarian cancer pathology characteristics as...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Protéine BRCA2 › Ovarian cancer pathology characteristics as...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Ovarian cancer pathology characteristics as...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Prédisposition génétique à une maladie › Ovarian cancer pathology characteristics as...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Ovarian cancer pathology characteristics as...